MonlunabantAlso known as INV-202
So-called peripheral CB1 inverse agonist; 2025 phase 2a: weight loss of 6.4 to 8.0 kg versus placebo, with dose-dependent withdrawals for adverse events.
C₂₆H₂₂ClF₃N₆O₃S
CAS 2712480-46-9
- Family
- ECS pharmacological toolAntagonist or inverse agonist
- Molar mass
- 591.00 g/mol
Updated on
In plain terms
Monlunabant blocks the CB1 receptor, as rimonabant did, a drug that was abandoned because its use was associated with negative mood and suicidal thoughts. It was designed not to enter the brain, but a mouse study suggests it acts there. A 2025 trial in adults with obesity showed weight loss versus placebo, with adverse effects (nausea, anxiety) that rise with the dose.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to Monlunabant: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of Monlunabant.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1Inverse agonistno measured value cited
CB1 inverse agonist; binding at the orthosteric site (cryo-EM); bias towards β-arrestin 2 inhibition over Gi; affinity value not found in the sources read (Kumari et al. 2024); peripheral restriction disputed in the mouse (Mullassaril et al. 2025)
Measured effects
Not characterised. No placebo-controlled human trial has measured the effects of Monlunabant, so no level is shown.
Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method
Pharmacology
Monlunabant is a CB1 receptor inverse agonist designed to act in the periphery. It answers a question raised by the discontinuation of rimonabant, whose use was occasionally associated with negative affect and suicidality (Meye et al. 2013): does the metabolic benefit of CB1 blockade come from peripheral receptors? The phase 2a trial published in 2025 by Knop and colleagues, double-blind against placebo, lasted 16 weeks in 243 adults with obesity and metabolic syndrome at 25 Canadian centres (10, 20 or 50 mg a day by mouth). At week 16, the weight difference versus placebo was −6.4 kg (10 mg), −6.9 kg (20 mg) and −8.0 kg (50 mg), the loss being only slightly greater at higher doses. Adverse events, mostly gastrointestinal and psychiatric, were dose dependent: 69%, 78% and 92% of participants against 69% on placebo; withdrawals for adverse events reached 13%, 27% and 42% against none on placebo, owing to nausea, anxiety, diarrhoea, irritability and sleep disorder. No deaths were reported, and the authors consider that lower doses need evaluation (Knop et al. 2025). In mice, monlunabant reduces appetite and blocks HU-210-induced hypothermia at the same doses, pointing to an action on central CB1 (Mullassaril et al. 2025).
Key sources.
- Knop FK et al. Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. Lancet Diabetes Endocrinol, 2025 (new tab)PMID 41038215
- Mullassaril P, Brodkin L, Brodkin J. Monlunabant suppresses appetite through a central mechanism. Behav Pharmacol, 2025 (new tab)PMID 39969070
- Kumari P et al. Structural mechanism of CB1R binding to peripheral and biased inverse agonists. Nat Commun, 2024 (new tab)PMID 39695122
- Meye FJ et al. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry, 2013 (new tab)PMID 23070073
- PubChem, monlunabant, CID 156861524 (identifiers and properties) (new tab)
History
- Source
- An entirely synthetic compound with no natural occurrence. It comes from a pharmaceutical development programme; no commercialisation was found.
Origin
Research tool
No biological pathway: monlunabant is a synthetic compound of the dihydropyrazole (pyrazoline) class bearing a sulfonylated acylguanidine, unrelated to the plant cannabinoid pathway.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It is not listed in the schedules of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025, text reviewed). No marketing authorisation was found: the molecule is in clinical development.
- France
Not classified: monlunabant is not on the ANSM consolidated list of narcotics (updated 16/02/2026) and this dihydropyrazole derivative falls within none of the generic families of that list. No marketing authorisation was found: it is an investigational drug studied in clinical trials.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Antagonist or inverse agonist
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Knop FK et al. Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. Lancet Diabetes Endocrinol, 2025 (new tab)PMID 41038215
- Mullassaril P, Brodkin L, Brodkin J. Monlunabant suppresses appetite through a central mechanism. Behav Pharmacol, 2025 (new tab)PMID 39969070
- Kumari P et al. Structural mechanism of CB1R binding to peripheral and biased inverse agonists. Nat Commun, 2024 (new tab)PMID 39695122
- Meye FJ et al. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry, 2013 (new tab)PMID 23070073
- PubChem, monlunabant, CID 156861524 (identifiers and properties) (new tab)
Identifiers
Names
- Common name
- Monlunabant (INV-202)
- IUPAC name
- N-[(E)-N'-[(E)-C-[(4S)-5-(4-chlorophenyl)-4-phenyl-3,4-dihydropyrazol-2-yl]-N-[4-(trifluoromethyl)phenyl]sulfonylcarbonimidoyl]carbamimidoyl]acetamide
- Other names
- INV-202 · MRI-1891 · monlunabantum
Identifiers
- Formula
- C₂₆H₂₂ClF₃N₆O₃S
- CAS
- 2712480-46-9
- PubChem CID
- 156861524(new tab)
- InChIKey
- GYJPQNPVIJXXTA-JOCHJYFZSA-N
- SMILES
- CC(O)
= NC(= N) N= C(NS(= O) (= O) c1ccc(C(F) (F) F) cc1) N1C[C@H] (c2ccccc2) C(c2ccc(Cl) cc2) = N1
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.